




		EMLc	ATC codes: <a href="#">L01AA06</a>
Indication	Other specified malignant neoplasms of the ovary	ICD11 code: <a href="#">2D23.Y</a>	
INN	Ifosfamide		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection		
EML status history	First added in 2009 ( <a href="#">TRS 958</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Tags	<a href="#">Cancer</a>		
Wikipedia	<a href="#">Ifosfamide</a> 		
DrugBank	<a href="#">Ifosfamide</a> 		

## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for ovarian germ cell tumour was specifically endorsed. Additionally, ifosfamide was included on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ovarian germ cell tumour is attached.

Expert Committee report 
